Lactobacillus Fermentum ME-3 Improvement in Dermatitis and Stroke
Title: Probiotics, Oxidative Stress, Inflammation and Diseases
Publication: 4th Central European Congress on Food. May 15-17, Caveat, Croatia.
Authors: Tiiu Kullisaar, Marika Mikelsaar, Sirje Kaur, Epp Songisepp, Kersti Zilmer, Pirje Jutt, Aet Lukmann, Jaak Maaroos, Jaak Kals, and Mihkel Zilmer
Part 1: Atopic Dermatitis:
11 patients with atopic dermatitis, ages 20-42 years old, randomized into 2 groups.
During the 3-month trial, 5 patients consumed goats’ milk with ME-3 while 6 people acted as placebo controls.
Results: Patients with atopic dermatitis generally have abnormalities of their glutathione-system along with increased oxidative stress, inflammation and often impaired skin membrane barrier function.
Individuals receiving ME-3 experienced significant improvements in skin condition, blood markers and in self-assessment rating scores.
Part 2: Brain Stroke:
21 patients (ages 71-89) who had experienced a brain stroke sometime between 8 to 22 days earlier were randomly divided into 2 groups.
Subjects consumed either 3 capsules of ME-3 twice daily or 3 placebo capsules twice daily for time that ranged from 10 days to 3 weeks.
Patients were evaluated on the Functional Independence Measure inventory (FIM) and on the Scandinavian Stroke Scale (SSS).
Stroke patients consuming ME-3 exhibited significant improvements in both the Scandinavian Stroke Scale and the Functional Independence Measure inventory.
Stroke patients also experienced impressive improvements in the following blood markers: oxidized LDL-cholesterol, glutathione levels & ratio of reduced to oxidized glutathione, total antioxidant capacity, paraoxonase enzyme activity as well as reductions in markers of inflammation and free radical damage.
Part 3: Assay of Blood & Urine Markers:
15 healthy volunteers, ages (40-65). After a 2-week introductory period, the volunteers were randomized into a double-blind, placebo-controlled, crossover trial.
Individuals ingested kefir with ME-3 or placebo kefir for two weeks.
After a 3-week wash-out period, new blood & urine samples were taken and then subjects crossed over to take the alternate regime for an additional 2 weeks.
Results: Volunteers taking ME-3 experienced improvements in all blood and urine markers evaluated compared to controls.
Doses of Lactobacillus fermentum ME-3 used in the Human Clinical Trials
In most of the studies where the test subjects were taking capsules containing Lactobacillus fermentum ME-3, the dose was one billion bacteria per day.
In the brain stroke study, the dose was 6 billion per day.
Kefir: The probiotic doses in kefir are substantially higher, providing approximately 20-30 billion bacteria per day.
Even though the daily dose of ME-3 is much higher in the kefir delivery method compared to the dose of ME-3 in capsules, it is interesting to note that the magnitude of the beneficial changes (oxidized LDL-cholesterol, PON enzyme activity and total antioxidant status) are quite similar in the kefir trials compared to the capsule trials.
This indicates large doses (20- 30 billion) do not provide additional benefit beyond moderate doses containing several billion bacteria.